Hardman Johnston Global Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$38.9M Buy
32,461
+642
+2% +$656K 1.37% 15
2026
Q1
$29.3M Sell
31,819
-380
-1% -$385K 1.39% 16
2025
Q4
$34.6M Buy
32,199
+20,752
+181% +$19.8M 1.65% 16
2025
Q3
$8.73M Sell
11,447
-6,302
-36% -$4.69M 0.43% 41
2025
Q2
$13.8M Sell
17,749
-386
-2% -$300K 0.61% 38
2025
Q1
$15M Sell
18,135
-588
-3% -$489K 0.72% 39
2024
Q4
$14.5M Buy
18,723
+9,376
+100% +$7.76M 0.6% 38
2024
Q3
$8.28M Buy
9,347
+2,819
+43% +$2.53M 0.32% 47
2024
Q2
$5.91M Buy
6,528
+5,729
+717% +$4.58M 0.23% 49
2024
Q1
$622K Buy
799
+232
+41% +$165K 0.02% 65
2023
Q4
$331K Buy
+567
New +$331K 0.01% 71

Other funds holding LLY

Hardman Johnston Global Advisors's LLY Position: Q2 2026 in Review

Hardman Johnston Global Advisors increased its Eli Lilly (LLY) stake by 2% in Q2 2026, buying an estimated $656K and bringing the position to 32,461 shares worth $38.9M. The position accounts for 1.37% of the portfolio, ranked #15.

Hardman Johnston Global Advisors first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. 4,633 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Hardman Johnston Global Advisors held 32,461 shares of Eli Lilly worth $38.9M as of Q2 2026.
  • Hardman Johnston Global Advisors bought 642 Eli Lilly shares in Q2 2026, an estimated $656K.
  • Eli Lilly made up 1.37% of Hardman Johnston Global Advisors's portfolio in Q2 2026, its #15 holding.
  • Hardman Johnston Global Advisors first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • 4,633 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Hardman Johnston Global Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.